Nitric oxide inhibition ameliorates cortical proteomic changes in the Cntnap2-/- and Shank3Δ4-22 mouse models of autism spectrum disorder.

Nothing here was measured in people. The whole study is in mouse cortex, so it cannot tell you whether inhibiting nitric oxide synthase helps any patient. The behavioural results were not a new experiment. Ten mice per group were re-analysed from data the group already had, and the paper states no new behavioural testing was done. The protein work used very small numbers: four mice per group in the Cntnap2 cohort and three per group in the Shank3 cohort. The follow-up western blot of three selected proteins did not reach statistical significance, so the mass spectrometry findings were not independently confirmed by a second method. Only the cortex was profiled. Other regions such as the striatum, amygdala and hippocampus were not examined. The authors note that 7-NI may have off-target effects, particularly at higher doses, and suggest more selective inhibitors or genetic models such as nNOS knockout mice for future work. Most of the altered proteins were only partially shifted toward wild-type levels rather than fully restored.

The funding declaration names four funders: the Eagles Autism Foundation, the Israel Science Foundation, the U.S. Department of Defense and the Deutsche Forschungsgemeinschaft. The supplied text contains no conflict-of-interest statement from the authors.

Do not read this as evidence that a nitric oxide inhibitor is a treatment for autism. The work is in mouse brain tissue, the behaviour results come from re-analysing older data rather than a new experiment, the western blot check of three proteins did not reach statistical significance, and the social novelty deficit did not improve in the Cntnap2 mice even though it did in the Shank3 mice.